Curated content that matters
Explore stories across diverse categories
Next Biomedical Co., a South Korean medical-device specialist, said it has received regulatory approval in Canada for its
Samsung Bioepis said it has reached a licensing and settlement agreement with Regeneron Pharmaceuticals Inc. and Bayer AG
South Korean President Lee Jae-myung has delivered one of his clearest warnings yet about the country’s industrial future,
President Lee Jae-myung has reopened a national policy discussion in South Korea by raising the possibility of imposing
Photo=Bighit Music South Korean entertainment stocks climbed after HYBE disclosed plans for a large-scale global tour by K-pop group BTS, with brokerages raising price targets and forecasting a rebound in the company’s earnings. HYBE shares closed up about 2% on Jan. 15, local time, according to exchange data released Jan. 16, while other major entertainment companies—including YG Entertainment, JYP Entertainment
Photo=Naver South Korea has moved to tighten the definition of “sovereign” artificial intelligence as it accelerates a state-backed effort to build a fully homegrown large language model—an ambitious bid to narrow its gap with the U.S. and China in the global AI race. On Jan. 15, the Ministry of Science and ICT said it had selected LG AI Research, SK
(Photo=Lotte) Lotte Group, one of South Korea’s largest conglomerates, is signaling a strategic pivot away from sales-driven expansion as it confronts slowing growth and mounting pressure to improve capital efficiency across its businesses. At a semiannual meeting of senior executives this week, Chairman Shin Dong-bin told top management that the company’s challenges cannot be resolved without abandoning long-standing management habits
(Photo=Dong-A ST) As the U.S. obesity drug market grows more crowded and capital-intensive, smaller biotech companies are increasingly relying on creative financing to stay in contention. MetaVia, a U.S.-based biotechnology company backed by South Korean pharmaceutical group Dong-A ST, is the latest to take that route. MetaVia said it raised about $8.1 million in gross proceeds through a registered public
(Photo=LivsMed) Rising costs and tighter capital budgets are forcing hospital systems to reexamine how they invest in surgical robotics, a category long shaped by a single dominant platform. That reassessment is beginning to draw overseas manufacturers that see room for alternatives, including LivsMed, a South Korean medical-device maker that is moving to establish a foothold after securing fresh capital from
